Monoclonal antibodies to target asthma

Research output: Contribution to journalArticle


Current therapies for asthma are aimed at controlling disease symptoms. For the majority of asthmatics glucocorticoid-based inhaled anti-inflammatory therapy is effective. However, a subset of patients remains symptomatic despite optimal treatment creating a clear unmet medical need. Biopharmaceutical approaches may identify small molecules that target key cells and mediators that drive the inflammatory responses underlying the pathogenesis of asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IgE, IL-4 and IL-5.
Original languageEnglish
Pages (from-to)6-8
Number of pages3
JournalBiotech Inernational
Issue number2
Publication statusPublished - 2010


Dive into the research topics of 'Monoclonal antibodies to target asthma'. Together they form a unique fingerprint.

Cite this